IGM Biosciences

Traded on the St. Petersburg Stock Exchange
IGM Biosciences is an American biotechnology company that specializes in the research and development for the treatment of cancer. It focused on creating and developing engineered IgM antibodies. The company's headquarters are in Mountain View, California.
IGM Biosciences stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

IGM Biosciences balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

IGM Biosciences cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

IGM Biosciences multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

IGM Biosciences profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
IGM Biosciences assets
IGM Biosciences cash flows

IGM Biosciences dividend policy

The company doesn't provide dividend

IGM Biosciences shares

TickerNameTypeNominal valueISINPrice
IGMS:USIGM BiosciencesCommon share-US4495851085$14.17
IGM Biosciences news
10.05.2022
IGM Biosciences' GAAP loss for 3 months of 2022 was $51.894 million, up 64% from $31.644 million in the previous year.
Source: {source} pictogram igmbio.gcs-web.com
Pictogram next
29.03.2022
IGM Biosciences' GAAP loss for 2021 was $165.164 million, up twofold from $81.355 million in the previous year.
Source: {source} pictogram igmbio.gcs-web.com
Pictogram next
04.11.2021
IGM Biosciences' GAAP loss for 9M 2021 was $114.522 million, doubling from $56.733 million in the previous year.
Source: {source} pictogram igmbio.gcs-web.com
Pictogram next
10.08.2021
IGM Biosciences' GAAP loss for 6M 2021 was $70.358 million, up 93% from $36.463 million in the previous year.
Source: {source} pictogram igmbio.gcs-web.com
Pictogram next
All IGM Biosciences news
General information
Company nameIGM Biosciences
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address325 East Middlefield Road Mountain View, CA 94043 United States
Mailing address325 East Middlefield Road Mountain View, CA 94043 United States
Websiteinvestor.igmbio.com
Information disclosurewww.sec.gov